Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.

J. Koska,P. Reaven,H. Gerstein,P. Beisswenger

DOI: https://doi.org/10.2337/dc21-2196

2022-01-20

Diabetes Care

Abstract:OBJECTIVE To evaluate the association of a multicomponent advanced glycation end product (AGE) panel with decline in kidney function and its utility in predicting renal function loss (RFL) when added to routine clinical measures in type 2 diabetes. RESEARCH DESIGN AND METHODS Carboxymethyl and carboxyethyl lysine and methylglyoxal, 3-deoxyglucosone, and glyoxal hydroimidazolones were measured in baseline serum and plasma samples, respectively, from Action to Control Cardiovascular Risk in Diabetes (ACCORD) (n = 1,150) and Veterans Affairs Diabetes Trial (VADT) (n = 447) participants. A composite AGE score was calculated from individual AGE z scores. The primary outcome was a sustained 30% decline in estimated glomerular filtration rate (eGFR) (30% RFL in both cohorts). Secondary outcomes (in ACCORD) were 40% RFL, macroalbuminuria, and high-risk chronic kidney disease (hrCKD). RESULTS After adjustment for baseline and follow-up HbA1c and other risk factors in ACCORD, the AGE score was associated with reduction in eGFR (β-estimate -0.66 mL/min ⋅ 1.73m2 per year; P = 0.001), 30% RFL (hazard ratio 1.42 [95% CI 1.13-1.78]; P = 0.003), 40% RFL (1.40 [1.13-1.74]; P = 0.003), macroalbuminuria (1.53 [1.13-2.06]; P = 0.006), and hrCKD (1.88 [1.37-2.57]; P < 0.0001). AGE score improved net reclassification (NRI) and relative integrated discrimination (IDI) for 30% RFL (NRI 23%; P = 0.02) (relative IDI 7%; P = 0.009). In VADT, the AGE score calculated by the ACCORD-derived coefficients was associated with 30% RFL (1.37 [1.03-1.82); P = 0.03) and improved NRI (24%; P = 0.03) but not IDI (P = 0.18). CONCLUSIONS These data provide further support for a causal role of AGEs in diabetic nephropathy independently of glycemic control and suggest utility of the composite AGE panel in predicting long-term decline in renal function.

Medicine

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the association between various components of advanced glycation end - products (AGEs) and the decline in renal function, and to explore whether the addition of AGEs to routine clinical indicators can better predict renal function loss (RFL), especially in patients with type 2 diabetes. Specifically, the study aims to evaluate the predictive value of a comprehensive score composed of multiple AGEs components for the decline in renal function (defined as a 30% decrease in the estimated glomerular filtration rate eGFR) and high - risk chronic kidney disease (hrCKD).

In the study design and methods section, the researchers measured specific AGEs components in baseline serum and plasma samples from two large - scale cohort studies, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the Veterans Affairs Diabetes Trial (VADT), including carboxymethyllysine, carboxyethyllysine, methylglyoxal, 3 - deoxyglucosone, and glyoxal hydroxymorpholine. Using these data, the researchers calculated a comprehensive AGE score and performed an association analysis between it and the primary outcome of renal function decline (a 30% decrease in eGFR) as well as other secondary outcomes (such as a 40% decrease in eGFR, macroalbuminuria, and high - risk chronic kidney disease).

The study results show that, after adjusting for HbA1c at baseline and during follow - up and other risk factors, the AGE score is significantly associated with an increased risk of eGFR decline, 30% and 40% RFL, macroalbuminuria, and hrCKD. In addition, the AGE score improves the net re - classification (NRI) and relative integrated discrimination improvement (IDI) for 30% RFL. These findings support the important role that AGEs play in the development of diabetic nephropathy and indicate that AGEs can be an effective tool for predicting long - term renal function decline, independent of glycemic control.